InvestWiser

Respiratorius AB

RESPNasdaq StockholmHealthcareMarket value 11 m SEK
1.43SEK +6.1%
last day · Price as of 18 November 2026

The answer first

Does Respiratorius beat the market?

No, Respiratorius has not beaten the market over the last year.

Respiratorius−32.2%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 34% of Nordic stocks

    • Quality89
    • Value24
    • Trend17

    No. 95 of 195 in healthcare

Max for seven days

Follow Respiratorius with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Respiratorius

From today, at a price of 1.43 SEK. Write why you follow Respiratorius, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Respiratorius

Your first answer is free, no account needed.

Do you own Respiratorius, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Respiratorius and a few more. Free, no card.

Past year against the exchange and Super Stock
Respiratorius−32.2%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Respiratorius has fallen 32.2% over the past year, including dividends.
  • Overall, Respiratorius ranks better than 34% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 97.6%. The price is 99.5% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

34

Quality, value and trend together. Better than 34% of Nordic stocks.

No. 95 of 195 in healthcare

Quality89
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 38 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity–
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−24.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value24
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 85 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.4
  • P/SPrice divided by sales957.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend17
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 135 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−41.8%
  • 6 months−38.2%
  • 9 months−4.7%
  • 12 months−32.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−27.8%
3 years, per year
−60.0%
5 years, per year
−56.9%
10 years, per year
−36.5%
Largest fall, 3 years
−97.6%
From a peak to the bottom
From the peak now
−99.5%
How far the price is from the peak
Volatility, 1 year
99.2%
How much the price swings over a year
Beta, 1 year
0.45
How much the price moves when the market moves

Return with dividends reinvested.

About Respiratorius

Respiratorius AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK.

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. Its products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. The company was incorporated in 1998 and is based in Lund, Sweden.

See the full analysis of Respiratorius.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market